Reblozyl: Uses, Dosage & Side Effects
An erythroid maturation agent for the treatment of anemia in adults with myelodysplastic syndromes (MDS) and beta-thalassemia
Reblozyl (luspatercept) is a first-in-class erythroid maturation agent used for the treatment of anemia in adults with myelodysplastic syndromes (MDS) and beta-thalassemia. It works by binding to select transforming growth factor-beta (TGF-β) superfamily ligands, thereby promoting late-stage red blood cell maturation in the bone marrow and increasing hemoglobin levels. Reblozyl is administered as a subcutaneous injection once every three weeks by a healthcare professional. In clinical trials, Reblozyl significantly reduced the need for red blood cell transfusions in MDS patients and improved hemoglobin levels in both transfusion-dependent and non-transfusion-dependent beta-thalassemia patients, representing a meaningful advancement in the management of these chronic hematological conditions.
Quick Facts: Reblozyl
Key Takeaways
- Reblozyl (luspatercept) is a first-in-class erythroid maturation agent that promotes late-stage red blood cell development by inhibiting aberrant TGF-β superfamily signaling in erythroid precursors.
- It is approved for treating anemia in adults with myelodysplastic syndromes (MDS) who require red blood cell transfusions, as well as anemia in adults with beta-thalassemia (both transfusion-dependent and non-transfusion-dependent).
- Reblozyl is given as a subcutaneous injection every 3 weeks, starting at 1 mg/kg body weight, with dose adjustments up to 1.75 mg/kg (MDS) or 1.25 mg/kg (beta-thalassemia) based on clinical response.
- Clinical trials (MEDALIST and BELIEVE) demonstrated significant reductions in transfusion burden and improvements in hemoglobin levels compared to placebo.
- Reblozyl must not be used during pregnancy due to the risk of fetal harm; effective contraception is required during treatment and for at least 3 months after the last dose.
What Is Reblozyl and What Is It Used For?
Reblozyl contains the active substance luspatercept, a recombinant fusion protein produced using Chinese hamster ovary (CHO) cell technology. Luspatercept is composed of a modified extracellular domain of the human activin receptor type IIB (ActRIIB) linked to the Fc portion of human immunoglobulin G1 (IgG1). This unique structure enables luspatercept to act as a ligand trap, selectively binding to certain members of the transforming growth factor-beta (TGF-β) superfamily, including GDF11 and activin B, which are key regulators of late-stage erythropoiesis.
In healthy individuals, erythropoiesis is a tightly regulated process whereby hematopoietic stem cells in the bone marrow differentiate through a series of stages to become mature red blood cells (erythrocytes). This process involves early progenitors (burst-forming unit-erythroid and colony-forming unit-erythroid) that respond primarily to erythropoietin (EPO), followed by late-stage precursors (proerythroblasts, basophilic, polychromatic, and orthochromatic erythroblasts) that undergo terminal maturation, including hemoglobin synthesis, nuclear condensation, and enucleation. In diseases such as MDS and beta-thalassemia, this late-stage maturation is severely impaired due to aberrant TGF-β superfamily signaling, leading to ineffective erythropoiesis, premature destruction of erythroid precursors in the bone marrow, and resulting anemia.
Luspatercept addresses this pathological mechanism by binding to and neutralizing the TGF-β superfamily ligands (particularly GDF11 and activin B) that are overexpressed in MDS and beta-thalassemia. By reducing the aberrant Smad2/3 signaling pathway in erythroid precursors, luspatercept promotes the maturation of late-stage erythroid cells, increases the number of functional red blood cells released into the circulation, and thereby raises hemoglobin levels. This mechanism is fundamentally different from erythropoiesis-stimulating agents (ESAs) such as epoetin alfa and darbepoetin alfa, which act primarily on early erythroid progenitors by mimicking EPO.
Myelodysplastic Syndromes (MDS)
Myelodysplastic syndromes are a group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, peripheral blood cytopenias, and a variable risk of progression to acute myeloid leukemia (AML). Anemia is the most common clinical manifestation of MDS, affecting approximately 90% of patients at some point during their disease course. Many MDS patients become dependent on regular red blood cell transfusions, which can lead to iron overload and associated organ damage, including cardiac, hepatic, and endocrine complications. Transfusion dependence is also associated with reduced quality of life and decreased overall survival.
Reblozyl is indicated for the treatment of anemia in adult patients with MDS who require red blood cell transfusions. In the pivotal MEDALIST trial, a phase III, randomized, double-blind, placebo-controlled study involving 229 patients with lower-risk MDS with ring sideroblasts (MDS-RS), luspatercept demonstrated statistically significant superiority over placebo in achieving transfusion independence. The primary endpoint, transfusion independence for 8 weeks or longer during weeks 1 through 24, was achieved by 38% of patients in the luspatercept group compared to 13% in the placebo group (p < 0.001). Furthermore, 28% of luspatercept-treated patients achieved transfusion independence for 12 weeks or longer, compared to 8% with placebo.
The subsequent COMMANDS trial, a phase III open-label, randomized study, compared luspatercept to epoetin alfa as first-line treatment for anemia in lower-risk MDS patients who were ESA-naive and required red blood cell transfusions. Results demonstrated that luspatercept was superior to epoetin alfa, with a significantly higher proportion of patients achieving transfusion independence for 12 weeks or longer with concurrent hemoglobin increase (59% vs. 31%). These landmark results led to expanded indications for Reblozyl as a first-line treatment option for MDS-associated anemia.
Beta-Thalassemia
Beta-thalassemia is a group of inherited blood disorders caused by mutations in the beta-globin gene, resulting in reduced or absent production of the beta-globin chains of hemoglobin. This leads to an imbalance between alpha and beta-globin chains, causing ineffective erythropoiesis, hemolysis, and chronic anemia. The disease ranges in severity from beta-thalassemia minor (trait), which is usually asymptomatic, to beta-thalassemia intermedia and beta-thalassemia major (also called transfusion-dependent thalassemia or TDT), which requires lifelong regular blood transfusions to maintain adequate hemoglobin levels.
Reblozyl is indicated for the treatment of anemia in adults with beta-thalassemia who require or do not require regular red blood cell transfusions. In the BELIEVE trial, a phase III, randomized, double-blind, placebo-controlled study involving 336 patients with transfusion-dependent beta-thalassemia, luspatercept demonstrated a significant reduction in transfusion burden compared to placebo. The primary endpoint, a reduction of at least 33% in transfusion burden with a concurrent reduction of at least 2 red blood cell units during weeks 13 through 24 compared with baseline, was achieved by 21.4% of luspatercept-treated patients compared to 4.5% with placebo (p < 0.001).
For non-transfusion-dependent beta-thalassemia (NTDT), the BEYOND trial demonstrated that luspatercept significantly increased mean hemoglobin levels from baseline compared with placebo. Patients treated with luspatercept achieved clinically meaningful hemoglobin increases of 1.0 g/dL or greater, which correlates with improvements in symptoms of anemia such as fatigue, exercise intolerance, and shortness of breath.
While erythropoiesis-stimulating agents (ESAs) like epoetin alfa act on early erythroid progenitors by mimicking the hormone erythropoietin, Reblozyl has a fundamentally different mechanism. It targets late-stage erythroid maturation by blocking aberrant TGF-β superfamily signaling. This makes Reblozyl effective in patients who have failed ESA therapy or who have conditions where ineffective erythropoiesis (not inadequate EPO stimulation) is the primary problem, such as MDS with ring sideroblasts and beta-thalassemia.
What Should You Know Before Taking Reblozyl?
Contraindications
Reblozyl must not be used in patients who have a known allergy (hypersensitivity) to luspatercept or to any of the other ingredients in the formulation, including citric acid monohydrate, sodium citrate, polysorbate 80, sucrose, hydrochloric acid, and sodium hydroxide. Importantly, Reblozyl is absolutely contraindicated during pregnancy. Based on its mechanism of action affecting the TGF-β signaling pathway, which plays a critical role in embryonic and fetal development, luspatercept may cause serious harm to the developing fetus. Women must have a negative pregnancy test before initiating treatment.
Reblozyl should also not be used in patients who require treatment to control extramedullary hematopoiesis (EMH). EMH is a condition in which blood cell production occurs outside the bone marrow, typically in the spleen, liver, or along the spinal column. While Reblozyl aims to improve erythropoiesis within the bone marrow, it may theoretically exacerbate EMH in patients with significant pre-existing extramedullary disease, potentially leading to serious complications such as spinal cord compression.
Warnings and Precautions
Several important warnings and precautions apply to Reblozyl treatment. Thromboembolic events, including deep vein thrombosis (DVT), pulmonary embolism (PE), ischemic stroke, and portal vein thrombosis, have been reported in clinical trials and post-marketing surveillance. Patients with beta-thalassemia who have had a splenectomy may be at particularly elevated risk for thromboembolic complications. Your doctor will evaluate additional risk factors, including the use of hormone replacement therapy and a personal history of prior thrombosis, and may implement prophylactic measures such as anticoagulation therapy to reduce your risk.
Hypertension (high blood pressure) has been commonly reported in patients receiving Reblozyl. Blood pressure should be measured and adequately controlled before initiating treatment and before each subsequent dose. If blood pressure cannot be adequately controlled, treatment with Reblozyl should be withheld until blood pressure has been brought to acceptable levels. Patients with pre-existing hypertension should be monitored closely throughout treatment.
Extramedullary hematopoiesis with spinal cord compression has been reported in patients treated with Reblozyl. Symptoms may include severe back pain that does not resolve, numbness or weakness in the limbs, loss of voluntary movements, and difficulty controlling bladder or bowel function (incontinence). If any of these symptoms occur, patients should seek immediate medical attention, as spinal cord compression can cause permanent neurological damage if not treated promptly.
Patients with conditions affecting bone strength, such as osteopenia or osteoporosis, may be at increased risk of fractures during Reblozyl treatment. This potential risk should be considered, particularly in patients with additional risk factors for fractures. Routine blood tests are required before each dose of Reblozyl to monitor hemoglobin levels and ensure they are appropriate for continued treatment. For patients with kidney problems, additional monitoring may be necessary.
Pregnancy and Breastfeeding
Reblozyl must not be used during pregnancy. Women of childbearing potential must use effective contraception during treatment and for at least 3 months after the last dose. A pregnancy test is required before starting treatment. If pregnancy occurs during treatment, Reblozyl must be discontinued immediately, and the patient should contact their healthcare provider. It is unknown whether luspatercept passes into breast milk; therefore, breastfeeding is not recommended during treatment and for 3 months after the last dose.
Luspatercept may also cause fertility problems in women. The TGF-β signaling pathway plays important roles in reproductive biology, and inhibition of this pathway by luspatercept may affect ovarian function and the ability to conceive. Women considering future pregnancy should discuss this potential risk with their healthcare provider before starting treatment.
Driving and Operating Machinery
Reblozyl may cause fatigue, dizziness, or fainting. Patients who experience these side effects should avoid driving or operating machinery until they know how Reblozyl affects them. If dizziness or lightheadedness occurs, patients should contact their healthcare provider promptly.
Children and Adolescents
Reblozyl is not recommended for use in children and adolescents under 18 years of age. The safety and efficacy of luspatercept have not been established in the pediatric population. Clinical studies of Reblozyl enrolled only adult patients aged 18 years and older.
How Does Reblozyl Interact with Other Drugs?
Luspatercept is a large recombinant fusion protein that, unlike small-molecule drugs, is not metabolized by cytochrome P450 (CYP) enzymes in the liver. Instead, it is expected to be cleared through general protein catabolism, similar to endogenous proteins and other therapeutic monoclonal antibodies. Consequently, traditional pharmacokinetic drug-drug interactions mediated by CYP enzyme inhibition or induction are not expected with Reblozyl. No formal drug interaction studies have been conducted.
Despite the absence of traditional pharmacokinetic interactions, healthcare providers should be aware of several important pharmacodynamic considerations when prescribing Reblozyl alongside other medications. Because Reblozyl increases red blood cell production and raises hemoglobin levels, concurrent use with other erythropoiesis-stimulating therapies (such as ESAs, including epoetin alfa and darbepoetin alfa) has not been studied and should be approached with caution. The combined effect on hemoglobin levels could potentially lead to excessive erythrocytosis, increasing the risk of thromboembolic events.
Additionally, given the reported risk of thromboembolic events with Reblozyl, particular attention should be paid to the concomitant use of medications that may further increase thrombotic risk. These include oral contraceptives, hormone replacement therapy, and certain other procoagulant agents. Conversely, patients on anticoagulant or antiplatelet therapy should be monitored appropriately, as changes in hemoglobin levels and red blood cell mass may affect the balance of hemostasis.
| Drug/Drug Class | Type | Clinical Consideration |
|---|---|---|
| Erythropoiesis-stimulating agents (ESAs) | Pharmacodynamic | Not studied in combination; potential risk of excessive hemoglobin increase and thrombosis |
| Hormone replacement therapy | Pharmacodynamic | May increase risk of thromboembolic events; assess individual risk factors |
| Oral contraceptives | Pharmacodynamic | May increase thrombotic risk, especially in splenectomized beta-thalassemia patients |
| Anticoagulants (warfarin, DOACs) | Monitoring | Monitor appropriately; hemoglobin changes may affect hemostatic balance |
| Iron chelation therapy | Complementary | May continue alongside Reblozyl; monitor iron levels as transfusion burden changes |
| Hydroxyurea | Complementary | Limited data on concurrent use in beta-thalassemia; consult physician |
Patients should always inform their healthcare provider about all medications they are currently taking, have recently taken, or plan to take, including prescription medications, over-the-counter drugs, vitamins, and herbal supplements. While Reblozyl is unlikely to have traditional drug interactions, the clinical context of each patient's medication regimen should be carefully considered to ensure safe and effective treatment.
What Is the Correct Dosage of Reblozyl?
Reblozyl is supplied as a lyophilized (freeze-dried) powder that must be reconstituted with sterile water for injection before administration. The reconstituted solution is administered as a subcutaneous (under the skin) injection by a doctor, nurse, or other qualified healthcare professional. Reblozyl is not intended for self-administration at home. Injection sites include the upper arm, thigh, or abdomen.
Adults with Myelodysplastic Syndromes (MDS)
MDS Dosing Schedule
- Starting dose: 1.0 mg/kg body weight, administered subcutaneously every 3 weeks
- Dose titration: If inadequate response after at least 2 consecutive doses (6 weeks) at the starting dose, the dose may be increased to 1.33 mg/kg
- Further titration: If still inadequate response after at least 2 consecutive doses at 1.33 mg/kg, the dose may be increased to 1.75 mg/kg
- Maximum dose: 1.75 mg/kg every 3 weeks
- Discontinuation: Consider if no reduction in transfusion burden after at least 9 weeks (3 doses) at the maximum dose level
Adults with Beta-Thalassemia
Beta-Thalassemia Dosing Schedule
- Starting dose: 1.0 mg/kg body weight, administered subcutaneously every 3 weeks
- Dose titration: If inadequate response after at least 2 consecutive doses (6 weeks) at the starting dose, the dose may be increased to 1.25 mg/kg
- Maximum dose: 1.25 mg/kg every 3 weeks
- Dose reduction or interruption: Required if hemoglobin rises too rapidly or exceeds target levels
| Parameter | MDS | Beta-Thalassemia |
|---|---|---|
| Starting dose | 1.0 mg/kg | 1.0 mg/kg |
| Maximum single dose | 1.75 mg/kg | 1.25 mg/kg |
| Dosing interval | Every 3 weeks | Every 3 weeks |
| Route | Subcutaneous injection | Subcutaneous injection |
| Dose titration steps | 1.0 → 1.33 → 1.75 mg/kg | 1.0 → 1.25 mg/kg |
| Max injection volume per site | 1.2 mL | 1.2 mL |
Dose Calculation
The total dose is calculated based on the patient's body weight in kilograms: Total dose (mg) = Dose level (mg/kg) x Patient's body weight (kg). For example, a patient weighing 70 kg receiving the starting dose would receive 70 mg of luspatercept. If the calculated dose requires more than 1.2 mL of reconstituted solution per injection site, the total volume should be divided equally and administered at separate injection sites on opposite sides of the body.
Missed Dose
If a dose of Reblozyl is missed or a scheduled appointment is delayed, the injection should be administered as soon as possible. Subsequent doses should then continue as prescribed, with a minimum interval of 3 weeks between doses. Patients should not receive a double dose to compensate for a missed injection.
Overdose
There is limited experience with luspatercept overdose. In the event of overdose, patients should be monitored for any signs or symptoms of adverse reactions, and appropriate supportive treatment should be initiated as necessary. Excessive doses may lead to an inappropriately high hemoglobin level, which could increase the risk of thromboembolic events. Blood pressure should be closely monitored, and dose adjustment or temporary discontinuation should be considered based on clinical assessment.
Children and Adolescents
Reblozyl is not recommended for use in patients under 18 years of age. No dosage recommendations can be made for the pediatric population, as the safety and efficacy of luspatercept have not been established in this age group.
Elderly Patients
No dose adjustment is required for elderly patients based on age alone. However, elderly patients may have a higher prevalence of comorbidities, including cardiovascular disease and renal impairment, which may require additional monitoring during Reblozyl treatment. In the MEDALIST trial, the majority of enrolled patients were over 65 years of age, and the safety and efficacy profile in elderly patients was consistent with the overall study population.
What Are the Side Effects of Reblozyl?
Like all medicines, Reblozyl can cause side effects, although not everyone will experience them. The side effects reported in clinical trials and post-marketing surveillance are categorized by frequency below. It is important to discuss any new or worsening symptoms with your healthcare provider, as some side effects may require dose adjustment or additional treatment.
Contact your doctor or seek emergency care immediately if you experience: difficulty walking or speaking, dizziness, loss of balance, numbness or paralysis on one side of the body, or blurred vision (possible stroke); tender swelling and tightness in the legs or arms (possible blood clot); severe back pain that does not resolve, numbness, weakness, or loss of bladder/bowel control (possible spinal cord compression); or swelling of the face, lips, tongue, or throat with difficulty breathing (allergic reaction).
Very Common
May affect more than 1 in 10 patients
- Fatigue or feeling weak
- Diarrhea
- Nausea
- Abdominal pain
- Dizziness and headache
- Cough
- Shortness of breath (dyspnea)
- Edema (swelling in legs or hands)
- High blood pressure (hypertension)
- Upper respiratory tract infection
- Influenza or flu-like symptoms
- Back, joint, or bone pain
- Difficulty sleeping (insomnia)
- Changes in blood tests (elevated liver enzymes, increased creatinine)
- Electrolyte abnormalities (cramping, dizziness, irregular heartbeat)
Common
May affect up to 1 in 10 patients
- Lower respiratory tract infection
- Fainting (syncope), feeling of spinning, confusion
- Decreased appetite
- Fractures caused by accidents
- Muscle pain and muscle weakness
- Chest pain
- Small round red/purple spots on the skin (petechiae)
- Easy bruising, nosebleeds, or bleeding gums
- Intense headache localized to one side (migraine)
- Rapid heartbeat (tachycardia)
- Injection site reactions (redness, burning, pain, swelling, itching)
- Kidney function impairment
- Excessive sweating
- High uric acid levels (hyperuricemia)
- Dehydration
- Urinary tract infection
- Foamy urine (proteinuria/albuminuria)
- Shortness of breath when exercising or lying down (possible heart failure)
Serious Side Effects
While most side effects of Reblozyl are mild to moderate in severity, several serious adverse reactions have been reported and require particular attention. Thromboembolic events, including stroke, deep vein thrombosis, pulmonary embolism, and portal vein thrombosis, represent one of the most clinically significant risks. In the MEDALIST trial, thromboembolic events occurred in 4.0% of luspatercept-treated patients compared to 1.7% in the placebo group. Patients with MDS who have a history of stroke or cardiovascular disease may be at higher risk. In beta-thalassemia patients, splenectomy is an additional risk factor for thrombosis.
Hypertension was reported in a significant proportion of patients in clinical trials. Blood pressure monitoring before each dose is mandatory, and treatment should be withheld if blood pressure is not adequately controlled. Extramedullary hematopoiesis with spinal cord compression, while rare, is a medical emergency that requires immediate intervention. Any symptoms suggestive of spinal cord compression (severe persistent back pain, limb weakness or numbness, bladder or bowel dysfunction) should prompt urgent medical evaluation and imaging studies.
Allergic reactions, including skin rash and swelling around the eyes, face, lips, or throat, have been reported. While most allergic reactions were mild, patients should be monitored for signs of hypersensitivity during and after administration. The reconstituted solution contains polysorbate 80, which may cause allergic reactions in sensitive individuals.
Regular blood tests are required before each dose of Reblozyl. Your healthcare provider will monitor your hemoglobin levels, blood pressure, kidney function, and liver enzymes throughout treatment. For patients with kidney problems, additional monitoring may be necessary. Report any new symptoms promptly to your healthcare team.
How Should You Store Reblozyl?
Reblozyl requires careful storage to maintain its stability and effectiveness. As a biological product (recombinant fusion protein), luspatercept is sensitive to temperature extremes, light exposure, and physical agitation. Proper storage conditions are essential to preserve the integrity of the protein structure and ensure safe and effective treatment.
Unopened Vials
Store unopened Reblozyl vials in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze the vials, as freezing can damage the protein structure and render the medication ineffective. Keep the vials in the original carton to protect them from light. Always check the expiration date printed on the carton and vial before use; the expiration date refers to the last day of the indicated month.
Reconstituted Solution
Once reconstituted with sterile water for injection, the Reblozyl solution should ideally be used immediately. If immediate use is not possible, the reconstituted solution may be stored in its original vial for up to 8 hours at room temperature (not exceeding 25°C / 77°F) or for up to 24 hours in a refrigerator at 2°C to 8°C (36°F to 46°F). The reconstituted solution must not be frozen. Any unused solution remaining after administration should be discarded according to local regulations for pharmaceutical waste.
Keep Reblozyl and all medicines out of the sight and reach of children. Do not dispose of medications through household waste or wastewater. Ask your pharmacist about proper disposal methods for medicines that are no longer needed, as these measures help protect the environment.
What Does Reblozyl Contain?
Reblozyl is a white to off-white lyophilized (freeze-dried) powder for solution for injection. It is supplied in single-use glass vials containing either 25 mg or 75 mg of luspatercept. After reconstitution with the appropriate volume of sterile water for injection, each milliliter of solution contains 50 mg of luspatercept (50 mg/mL). Each carton contains one vial.
Active Ingredient
The active substance is luspatercept, a recombinant fusion protein consisting of a modified extracellular domain of the human activin receptor type IIB (ActRIIB) linked to the Fc portion of human IgG1. It is produced in Chinese hamster ovary (CHO) cells using recombinant DNA technology.
Other Ingredients (Excipients)
- Citric acid monohydrate (E330): Buffer to maintain pH stability
- Sodium citrate (E331): Buffer to maintain pH stability
- Polysorbate 80 (E433): Surfactant to stabilize the protein. Note: polysorbate 80 may cause allergic reactions in some individuals (0.1 mg per 25 mg vial; 0.3 mg per 75 mg vial)
- Sucrose: Cryoprotectant and stabilizer
- Hydrochloric acid: For pH adjustment
- Sodium hydroxide: For pH adjustment
This medicine contains less than 1 mmol (23 mg) sodium per dose, meaning it is essentially sodium-free. Patients on controlled sodium diets can use this medicine without concern for sodium intake.
| Vial Strength | Water for Injection Required | Final Concentration | Deliverable Volume |
|---|---|---|---|
| 25 mg | 0.68 mL | 50 mg/mL | 0.5 mL |
| 75 mg | 1.6 mL | 50 mg/mL | 1.5 mL |
When properly reconstituted, the solution should appear colorless to slightly yellow, clear to slightly opalescent, and free from visible foreign particles. Do not use the solution if undissolved product or foreign particles are observed. The reconstitution process involves gently swirling the vial (not shaking) to dissolve the powder, which typically takes several minutes. Detailed reconstitution instructions are provided in the package insert and should be followed precisely by the healthcare professional administering the injection.
Frequently Asked Questions About Reblozyl
Reblozyl (luspatercept) is used to treat anemia in adults with two distinct conditions: myelodysplastic syndromes (MDS) who require red blood cell transfusions, and beta-thalassemia (both transfusion-dependent and non-transfusion-dependent). It works by promoting the maturation of red blood cells in the bone marrow, increasing hemoglobin levels, and reducing or eliminating the need for blood transfusions.
Reblozyl is given as a subcutaneous injection (under the skin) by a healthcare professional once every 3 weeks. It is supplied as a powder that must be reconstituted before injection. The injection is given in the upper arm, thigh, or abdomen. Unlike some other injectable medications, Reblozyl is not designed for self-administration at home.
The most common side effects include fatigue, diarrhea, nausea, dizziness, back pain, headache, cough, shortness of breath, high blood pressure, swelling (edema), and upper respiratory tract infection. Most side effects are mild to moderate. Serious side effects such as blood clots and spinal cord compression are uncommon but require immediate medical attention.
No, Reblozyl must not be used during pregnancy. Based on its mechanism of action, luspatercept may cause harm to the developing fetus. Women of childbearing potential must use effective contraception during treatment and for at least 3 months after the last dose. A pregnancy test is required before starting treatment. Breastfeeding is also not recommended during treatment and for 3 months after the last dose.
Response times vary between patients. Some patients begin to see improvements within the first few treatment cycles (6 to 12 weeks), while others may need dose adjustments over several months. Your doctor will monitor your hemoglobin levels and transfusion requirements to assess your response. If there is no meaningful improvement after appropriate dose escalation over at least 9 weeks, your doctor may consider discontinuing treatment.
While ESAs (such as epoetin alfa) mimic the hormone erythropoietin and stimulate early-stage red blood cell precursors, Reblozyl works at a later stage of red blood cell development. It targets aberrant TGF-β superfamily signaling that prevents proper maturation of red blood cells in MDS and beta-thalassemia. This makes Reblozyl effective in patients who have not responded to ESA therapy, and in the COMMANDS trial, Reblozyl was actually shown to be superior to epoetin alfa as first-line treatment for MDS-associated anemia.
References
- European Medicines Agency (EMA). Reblozyl (luspatercept) Summary of Product Characteristics. Last updated 2025. Available at: ema.europa.eu
- U.S. Food and Drug Administration (FDA). Reblozyl (luspatercept-aamt) Prescribing Information. Revised 2024. Available at: accessdata.fda.gov
- Fenaux P, Platzbecker U, Mufti GJ, et al. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes (MEDALIST trial). N Engl J Med. 2020;382(2):140-151. doi:10.1056/NEJMoa1908083
- Cappellini MD, Viprakasit V, Taher AT, et al. A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia (BELIEVE trial). N Engl J Med. 2020;382(13):1219-1231. doi:10.1056/NEJMoa1910182
- Platzbecker U, Della Porta MG, Santini V, et al. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS trial). Lancet. 2023;402(10399):373-385. doi:10.1016/S0140-6736(23)00874-7
- National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Myelodysplastic Syndromes. Version 1.2025.
- Thalassaemia International Federation (TIF). Guidelines for the Management of Transfusion Dependent Thalassaemia. 4th Edition, 2023.
- World Health Organization (WHO). Model List of Essential Medicines. 23rd List, 2023.
Medical Editorial Team
Medical Content
iMedic Medical Editorial Team – Specialists in Hematology and Clinical Pharmacology
Medical Review
iMedic Medical Review Board – Independent review according to international guidelines (WHO, EMA, FDA, NCCN)
Evidence Framework
GRADE (Grading of Recommendations, Assessment, Development and Evaluations) – Evidence Level 1A
Independence
No pharmaceutical company sponsorship. No commercial funding. All content is independently produced and reviewed.
All medical information on iMedic is written and reviewed by qualified healthcare professionals with expertise in the relevant medical specialty. Our editorial process follows the GRADE evidence framework, and all content is regularly updated to reflect the latest clinical guidelines and peer-reviewed research. For more information, see our Medical Team and Editorial Standards pages.